GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » Sloan Ratio %

Applied Therapeutics (Applied Therapeutics) Sloan Ratio % : 0.00% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Applied Therapeutics's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.00%.

Warning Sign:

When sloan ratio (-143.09)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Dec. 2023, Applied Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Applied Therapeutics Sloan Ratio % Historical Data

The historical data trend for Applied Therapeutics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics Sloan Ratio % Chart

Applied Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial 22.32 3.56 -30.36 -45.84 -143.09

Applied Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.84 -87.88 - - -

Competitive Comparison of Applied Therapeutics's Sloan Ratio %

For the Biotechnology subindustry, Applied Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Therapeutics's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Therapeutics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Applied Therapeutics's Sloan Ratio % falls into.



Applied Therapeutics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Applied Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-119.763--55.173
-13.872)/54.833
=-143.09%

Applied Therapeutics's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-119.763--55.173
-13.872)/54.833
=-143.09%

Applied Therapeutics's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -10.137 (Mar. 2023 ) + -29.577 (Jun. 2023 ) + -42.37 (Sep. 2023 ) + -37.679 (Dec. 2023 ) = $-119.76 Mil.
Applied Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -6.99 (Mar. 2023 ) + -16.452 (Jun. 2023 ) + -14.726 (Sep. 2023 ) + -17.005 (Dec. 2023 ) = $-55.17 Mil.
Applied Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 13.872 (Mar. 2023 ) + 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) = $13.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied Therapeutics  (NAS:APLT) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Applied Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Applied Therapeutics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Therapeutics (Applied Therapeutics) Business Description

Traded in Other Exchanges
Address
545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need.
Executives
Stacy J. Kanter director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman director, 10 percent owner, officer: President and CEO C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Adam Hansard officer: Chief Commercial Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Riccardo Perfetti officer: Chief Medical Officer C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc. 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Catherine Thorpe officer: Chief Accounting Officer 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan officer: Chief Accounting Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega officer: Principal Accounting Officer C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein officer: Chief Financial Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler director DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173

Applied Therapeutics (Applied Therapeutics) Headlines

From GuruFocus